NEWS
More information
NEWS
Dr. Jin Lei: The research on long-acting growth hormone has achieved remarkable results, and the matching electronic pen will be launched soon
Release time:
2021-09-15
Recently, Jinsai Pharmaceuticals joined hands with nearly 30 top experts in the field of pediatrics at home and abroad to open the 6th Jizhi Summit Academic Ceremony. Dr. Jin Lei, Chief Scientist of Kinsai Pharmaceuticals, attended the meeting and delivered a keynote speech.
Dear experts and teachers:
Hello everyone! I am very happy to take this opportunity to share the latest exploration and research of Kinsey Pharma in the field of pediatric endocrinology.
continue to advance,
Significant progress in long-acting growth hormone research
As a partner of domestic pediatric endocrinology, Kinsey has been working in the same direction with the Endocrine Genetics and Metabolism Group of the Pediatric Branch of the Chinese Medical Association to create research together. Although affected by the epidemic in the past two years, our research in related fields has continued to advance steadily.
One of the most important achievements is a series of studies around long-acting growth hormone. First, we have accumulated a lot of evidence around its safety. Secondly, in the exploration of new indications including ISS, SGA, TS, etc., there has also been considerable progress with the support of experts, and it is believed that it will be approved soon. In addition, the long-acting growth hormone packaged in the cartridge has been officially approved by the State Food and Drug Administration, and the crypto-needle electronic injection pen used in conjunction with it will also be officially launched in the summer, which is believed to further improve the comfort of long-acting growth hormone therapy. , but also to provide patients with more convenient treatment.
rapid transformation,
Create multiple R&D technology platforms
Over the years, through in-depth discussions with experts in the field and the actual problems reported by parents, we have fully realized that there are still a lot of unmet clinical needs in the field of pediatric endocrinology, including precocious puberty, obesity, adrenal diseases, etc. Therefore, we decided to quickly promote the overall strategic transformation of Kinsey. From a drug manufacturer focusing on a single product, it has rapidly transformed into a multi-advanced R&D technology platform, and is committed to becoming an excellent pharmaceutical company in the field of children's and women's health.
To this end, we will continue to invest more energy in the field of new drug research and development, build more technology platforms, focus on solving children's and women's health problems, and continue to deepen the field of pediatric endocrinology based on diseases related to children's health. In the next few years, the R&D team will gradually expand from the current 2,000 people to 5,000 people, and at the same time, it will continue to increase R&D investment at a rate that exceeds 15% of sales revenue. It will also intervene in the fields of medical devices and artificial intelligence. In a word, through the construction of a series of technology platforms and product development, we hope to provide Chinese children with a complete growth and development in the aspects of prevention and early screening, diagnosis and type confirmation, rehabilitation and patient management, treatment and effect evaluation, etc. Health management platform.
For the research and development of new products and related research work, we will change from focusing on internal research and development in the past to incubating and co-creating with experts in the field. In the past two years, we have carried out a considerable amount of research with a series of top academic institutions and universities in China, including cooperation on childhood obesity, growth and development, artificial intelligence, children's mental and neurological aspects, and we believe that we will continue to develop new products in the field of children's growth and development. , providing more and more comprehensive management tools for children's health, and will also play a certain role in promoting the development of scientific research in various fields.
Rich product line,
Help solve the medical problem of "stuck neck"
In addition, we will rapidly expand on the basis of genetically engineered pharmaceuticals, focusing on building a number of new technology platforms including gut microbes, long-acting, and AI algorithms to help solve the medical problem of "stuck neck". At the same time, a series of product lines have been developed around different disease areas, and the types of products are constantly enriched.
At present, we have deployed more than 20 innovative molecules with global competitiveness in the field of children's health. In the future, with the progress of the product stage, we also look forward to having more opportunities to create together with experts and teachers. We also hope that through our continuous investment and more and more extensive international exchanges, we can provide experts and children with clinical solutions that can keep pace with or catch up with the world.
Provide a comprehensive health plan,
Use technology to protect children's future
In the past 20 years, we have focused on the innovation of growth hormone. In the future, we hope to truly achieve a new historical stage, and truly transform from a growth hormone research and development enterprise into a new drug innovation research and development platform focusing on children's health and women's health, and become a platform for the whole of China and even the whole of China. A company that provides the latest, best and most comprehensive health management solutions for children and women around the world, and truly realizes the vision of "protecting children's future with technology".
Finally, we sincerely hope that there will be more opportunities to continue to develop together with experts in the field of endocrinology, jointly innovate products, and jointly promote comprehensive scientific and technological innovation in the field of children's endocrinology and children's general health, so that Chinese children will be healthier, and the health level of the whole society can walk in the whole world. the forefront of the world.
Maybe you want to know more:
Jilin Province Jinpaige Pharmaceutical Co., Ltd.
Contact: Guan Ping
Service Hotline：13704437972
Company email：guanping@gensci-china.com
Company address: Xiashi Economic and Technological Development Zone, Dunhua City, Yanbian Prefecture, Jilin Province
WeChat public account
Mobile browsing